Therapeutic potential of cannabinoid medicines

Drug Testing and Analysis

Volumn 6, Issue 1-2, 2014, Pages 24-30

  Robson, P J ^a  

^a Porton Down Science Park   (United Kingdom)

Author keywords

Cannabidiol; Cannabinoids; Endocannabinoid system; Medicinal cannabis; Tetrahydrocannabinol

Indexed keywords

BEHAVIORAL RESEARCH; DISEASES; PHYSIOLOGICAL MODELS; PHYSIOLOGY;

CANNABIDIOL; CANNABINOIDS; CLINICAL RESEARCH; ENDOCANNABINOID; ENDOCANNABINOID SYSTEM; MEDICINAL CANNABIS; RECREATIONAL DRUGS; TETRAHYDROCANNABINOL; THERAPEUTIC POTENTIALS; TWENTIETH CENTURY;

CLINICAL RESEARCH;

DRONABINOL; ENDOCANNABINOID; MEDICAL CANNABIS; NABIXIMOLS; RECREATIONAL DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADDICTION; CHRONIC PAIN; DRUG TARGETING; EPILEPSY; HUMAN; LOSS OF APPETITE; METABOLIC DISORDER; MULTIPLE SCLEROSIS; NAUSEA AND VOMITING; NEOPLASM; NEUROPATHIC PAIN; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; WEIGHT REDUCTION;

CANNABIDIOL; CANNABINOIDS; ENDOCANNABINOID SYSTEM; MEDICINAL CANNABIS; TETRAHYDROCANNABINOL;

ANIMALS; APPETITE STIMULANTS; CANNABINOID RECEPTOR AGONISTS; CANNABINOIDS; CANNABIS; CHRONIC PAIN; EPILEPSY; HUMANS; MULTIPLE SCLEROSIS; NAUSEA; PSYCHOTIC DISORDERS; VOMITING;

EID: 84892458308     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1529     Document Type: Review

References (104)

1. R. Mechoulam. The pharmacohistory of cannabis sativa, in Cannabinoids as Therapeutic Agents, (Ed: R. Mechoulam). CRC Press, Roca Raton, 1986, pp. 1-19.
2. L. Grinspoon, J.B. Bakalar, Cannabis as a medicine, in Marijuana: The Forbidden Medicine. Yale University Press: New Haven, 1993, pp. 67-81.
3. W.B. O'Shaughnessy. On the cannabis indica or Indian hemp. Pharmacol. J. 1843, 2, 594.
4. I. Grant, J. H. Atkinson, B. Gouaux, B. Wilsey. Medical marijuana: Clearing away the smoke. Open Neuro. J. 2012, 6, 18.
5. Y. Gaoni, R. Mechoulam. Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 1964, 86, 1646.
6. W.D.M. Paton. The pharmacology of marijuana. Annu. Rev. Pharmacol. 1975, 15, 191.
7. W. A. Devane, L. Hanus, A. Breuer, R. G. Pertwee, L. A. Stevenson, G. Griffin, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258(5090), 1946.
8. S. Munro, K. L. Thomas, M. Abu-Shaar. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365(6441), 61.
9. V. Di Marzo, M. Bifulco, L. De Petrocellis. The endocannabinoid system and its therapeutic exploitation. Nat. Rev. 2004, 3, 771.
10. K. Mackie, Distribution of cannabinoid receptors in the central and peripheral nervous system, in Cannabinoids, (Ed. R. Pertwee). Springer-Verlag, Berlin Heidelberg, 2005, pp. 299-325.
11. P. Pacher, S. Batkai, G. Kunos. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 2006, 58, 389.
12. E. B. Russo. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Brit. J. Pharmacol. 2011, 163, 1344.
13. R. G. Pertwee. Cannabinoid pharmacology: The first 66years. Brit. J. Pharmaocol. 2006, 147, S163.
14. B. Costa. On the pharmacological properties of delta-9-tetrahydrocannabinol (THC). Chem. Biodivers. 2007, 4, 1664.
15. D. Nutt, L. A. King, W. Saulsbury, C. Blakemore. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 2007, 369, 1047.
16. P. Robson. Abuse potential and psychoactive effects of Δ-9-tetrahydrocannabinol and cannabinoid oromucosal spray (Sativex), a new cannabinoid medicine. Exp. Opin. Drug Saf. 2011, 10, 1.
17. D. C. D'Souza, R. A. Sewell, M. Ranganathan. Cannabis and psychosis/schizophrenia: Human studies. Eur. Arch. Psy. Clin. N. 2009, 259, 413.
18. M. Frisher, I. Crome, O. Martino, P. Croft. Assessing the impact of cannabis use on trends in diagnosed schizphrenia in the United Kingdom from 1996 to 2005. Schizophr. Res. 2009, 113, 123.
19. 9-tetrahydrocannabinol in man. Eur. J. Pharmacol. 1974, 28(1), 172.
20. C. J. A. Morgan, G. Schafer, T. P. Freeman, H. V. Curran. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: Naturalistic study. Brit. J. Psych. 2010, 197, 285.
21. C. J. A. Morgan, H. V. Curran. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Brit. J. Psychol. 2008, 192, 306.
22. S. Bhattacharyya, P. D. Morrison, P. Fusar-Poli, R. Martin-Santos, S. Borgwardt, T. Winton-Brown, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010, 35, 764.
23. M. Bifulco, C. Grimaldi, P. Gazzero, S. Pisanti, A. Santoro. Rimonabant: Just an anti-obesity drug? Current evidence on its pleiotropic effects. Mol. Pharmacol. 2007, 71, 1445.
24. F. J. Meye, V. Trezza, L. J. Vanderschuren, G. M. Ramakers, R. A. Adan. Neutral antagonism at the cannabinoid 1 receptor: A safer treatment for obesity. Mol. Psychiatr. 2012, DOI: 10.1038/mp.2012.145
25. A. J. Thompson. Symptomatic management and rehabilitation in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2001, 71, S2:ii, 22.
26. D. Baker, G. Pryce, J. L. Croxford, P. Brown, R.G. Pertwee, J.W. Huffman, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000, 404, 84.
27. A. Hilliard, C. Stott, S. Wright, G. Guy, G. Pryce, S. Al-lzki, et al. Evaluation of the effects of Sativex (THC BDS: CBD BDS) on inhibition of spasticity in a chronic relapsing experimental allergic autoimmune encephalomyelitis: A model of multiple sclerosis. ISRN Neurol. 2012, DOI: 10.5402/2012/802649
28. D. J. Petro, C. Ellenberger. The treatment of human spasticity with delta-9-THC. J. Clin. Pharmacol. 1981, 21, 413.
29. D. B. Clifford. THC for tremor in multiple sclerosis. Ann. Neurol. 1983, 13, 669.
30. H. M. Meinck, P. W. Schonle, B. Conrad. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J. Neurol. 1989, 236, 120.
31. R. Brenneissen, A. Egli, M. A. Elsohly, V. Henn, Y. Spiess. The effect of orally and rectally administered delta-9-THC on spasticity: A pilot study with two patients. Int. J. Clin. Pharm. Th. 1996, 34, 446.
32. P. Consroe, R. Musty, J. Rein, W. Tillery, R. Pertwee. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur. Neurol. 1997, 38, 44.
33. C. Vaney, P. Jobin, F. Tschopp, M. Heinzel, M. Schnelle. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis, in Symposium of the Cannabinoids, International Cannabinoid Research Society. 2002, pp. 57.
34. J. Killestein, E. L. Hoogervorst, M. Reif, N. F. Kalkers, A. C. Van Loenen, P. G. Staats, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002, 58, 1404.
35. J. Zajicek, P. Fox, H. Sanders, D. Wright, J. Vickery, A. Nunn, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet 2003, 362, 1517.
36. J. F. Fleuren, G. E. Voerman, C. V. Erren-Wolters, G. J. Snoek, J. S. Rietman, H. J. Hermens, et al. Stop using the Ashworth scale for the assessment of spasticity. J. Neurol. Neurosurg. Psychiat. 2010, 81, 46.
37. J. P. Zajicek, H. P. Sanders, D. E. Wright, P. J. Vickery, W. M. Ingram, S. M. Reilly, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12months follow up. J. Neurol. Neurosurg. Psychiat. 2005, 76, 164.
38. J. P. Zajicek, J. C. Hobart, A. Slade, D. Barnes, P. G. Mattison. Multiple sclerosis and extract of cannabis: Results of the MUSEC trial. J. Neurol. Neurosurg. Psychiat. 2012, 83, 1125.
39. D. T. Wade, P. Robson, H. House, P. Makela, J. Aram. A preliminary controlled study to determine whether whole plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehab. 2003, 17, 18.
40. D. T. Wade, P. Makela, H. House, C. Bateman, P. Robson. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler. J. 2004, 10, 434.
41. D. T. Wade, P. M. Makela, H. House, C. Bateman, P. Robson. Long-term use of a cannabinoid-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult. Scler. J. 2006, 12, 639.
42. C. M. Brady, R. DasGupta, C. Dalton, O. J. Wiseman, K. J. Berkley, C. J. Fowler. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult. Scler. J. 2004, 10, 425.
43. D. J. Rog, T. J. Nurmikko, T. Friede, C. A. Young. Randomised, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005, 65, 812.
44. C. Collin, P. Davies, I. K. Mutiboko, S. Ratcliffe, Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur. J. Neurol. 2007, 14, 290.
45. R. B. C. Kavia, C. De Ridder, C. S. Constantinescu, et al. Randomised controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult. Scler. J. 2010, 16, 1349.
46. M. G. Serpell, W. Notcutt, C. Collin. Sativex long-term use: An open-label trial in patients with spasticity due to multiple sclerosis. J. Neurol. 2013, 260(1), 285.
47. R. M. Langford, J. Mares, A. Novotna, M. Vachova, I. Novakova, W. Notcutt, et al. Ratcliffe. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J. Neurol. 2013, 260(4), 984.
48. D. J. Rog, T. J. Nurmikko, C. A. Young. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial. Clin. Ther. 2007, 29(9), 2068.
49. A. Novotna, J. Mares, S. Ratcliffe, I. Novakova, M. Vachova, O. Zapletalova, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol. 2011, 18, 1122.
50. A. Curtis, C. E. Clarke, H. E. Rickards. Cannabinoids for Tourette's syndrome. Cochrane Database Syst. Rev. 2009, DOI: 10.1002/14651858.CD006565.pub2
51. E. B. Russo, G. W. Guy, P. J. Robson. Cannabis, pain and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem. Biodivers. 2007, 4, 1729.
52. E. de Lago, J. Fernandez-Ruiz. Cannabinoids and neuroprotection in motor-related disorders. CNS Neurol. Disord. Drug Targets 2007, 6, 377.
53. R. Freynhagen, M. I. Bennett. Diagnosis and management of neuropathic pain. Brit. Med. J. 2009, 339, b3002.
54. J. M. Walker, A. G. Hohmann, Cannabinoid mechanisms of pain suppression, in Cannabinoids, (Ed: R. Pertwee). Springer-Verlag, Berlin, Heidelberg, 2005, pp. 509-554.
55. W. Notcutt, M. Price, G. Chapman. Clinical experience with nabilone for chronic pain. Pharm. Sci. 1997, 3, 551.
56. K. B. Svendsen, T. S. Jensen, F. W. Bach. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Brit. Med. J. 2004, 329, 253.
57. W. Notcutt, M. Price, R. Miller, S. Newport, C. Phillips, S. Simmons, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 'n of 1' studies. Anaesthesia 2004, 59, 440.
58. J. S. Berman, C. Symonds, R. Birch. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Results of a randomised controlled trial. Pain 2004, 112, 29.
59. T. J. Nurmikko, M. G. Serpell, B. Hoggart, P. J. Toomey, B. J. Morlion, D. Haines. Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial. Pain 2007, 133, 210.
60. R. Noyes, S. F. Brunk, D. A. Baram, A. Canter. Analgesic effects of delta-9-THC. J. Clin. Pharmacol. 1975, 15, 139.
61. R. Noyes, S. F. Brunk, D. H. Avery, A. Canter. The analgesic properties of delta-9-THC and codeine. Clin. Pharmacol. Ther. 1975, 18, 84.
62. J. R. Johnson, M. Burnell-Nugent, D. Lossignol, E. D. Ganae-Motan, R. Potts, M. T. Fallon. Multicenter, double-blind, randomised, placebo-controlled, parallel-group study of the efficacy, safety and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J. Pain Symptom Manag. 2010, 39, 167.
63. J. R. Johnson, D. Lossignol, M. Burnell-Nugent, M. T. Fallon. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J. Pain Symptom Manag. 2012, DOI: pii: S0885-3924(12)00439-3
64. R. K. Portenoy, E. D. Ganae-Motan, S. Allende, R. Yanagihara, L. Shaiova, S. Weinstein, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: A randomized, placebo-controlled, graded-dose trial. Pain 2012, 13, 438.
65. T. W. Klein. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 2005, 5, 400.
66. M. A. Ware, H. Adams, G. W. Guy. The medicinal use of cannabis in the UK: Results of a nationwide survey. Int. J. Clin. Pract. 2005, 59, 291.
67. A. M. Malfait, R. Gallily, P. F. Sumariwalla, A. S. Malik, E. Andreakos, R. Mechoulam, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. U. S. A. 2000, 97(17), 9561.
68. D. R. Blake, P. Robson, M. Ho, R. W. Jubb, C. S. McCabe. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 2006, 45, 50.
69. L. A. Parker, E. M. Rock, C. L. Limebeer. Regulation of nausea and vomiting by cannabinoids. Brit. J. Pharmacol. 2011, 163, 141.
70. J. S. Penta, D. S. Poster, S. Bruno, J. S. Macdonald. Clinical trials with anti-emetic agents in cancer patients receiving chemotherapy. J. Clin. Pharmacol. 1981, 21, 11.
71. M. Levitt, Cannabinoids as antiemetics in cancer chemotherapy, in Cannabinoids as Therapeutic Agents. (Ed: R. Mechoulam), CRC Press, Boca Raton, 1986, pp. 71-83.
72. T. F. Plasse, R. W. Gorter, S. H. Krasnow, M. Lane, K. V. Shepard, R. G. Wadleigh. Recent clinical experience with dronabinol. Pharmacol. Biochem. Be. 1991, 40, 695.
73. B. Todaro. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. J. Natl. Compr. Canc. Netw. 2012, 10, 487.
74. M. Duran, E. Pérez, S. Abanades, X. Vidal, C. Saura, M. Majem, et al. Preliminary efficacy and safety of an oromucosal standardised cannabis extract in chemotherapy-induced nausea and vomiting. Brit. J. Clin. Pharm. 2010, 70(5), 656.
75. T. C. Kirkham, C. M. Williams. Endogenous cannabinoids and appetite. Nutr. Res. Rev. 2001, 14, 65.
76. J. E. Beal, R. Olson, L. Laubenstein, J. O. Morales, P. Bellman, B. Yangco, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J. Pain Symptom Manag. 1995, 10, 89.
77. J. E. Beal, R. Olson, L. Lefkowitz, L. Laubenstein, P. Bellman, B. Yangco, et al. Long-term efficacy and safety of dronabinol for acquired immuned deficiency syndrome-associated nausea. J. Pain Symptom Manag. 1997, 21, 214.
78. R. A. Kaslow, W. C. Blackwelder, D. G. Ostrow, D. Yerg, J. Palenicek, A. H. Coulson, et al. No evidence for a role of alcohol or other psychoactive drugs in accelerating immune deficiency in HIV-1 positive individuals. JAMA 1989, 261, 3424.
79. B. M. Bredt, D. Higueral-Alhino, S. B. Shade, S. J. Hebert, J. M. McCune, D.I. Abrams. Short term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. J. Clin. Pharmacol. 2002, 42, 82.
80. D. I. Abrams, J. F. Hilton, R. J. Leiser, S. B. Shade, T. A. Elbeik, F. T. Aweeka, et al. Short-term effects of cannabinoids in patients with HIV-1 infection. A randomized, placebo-controlled clinical trial. Ann. Intern. Med. 2003, 139, 258.
81. W. Regelson, J. R. Butler, J. Schulz, T. Kirk, L. Peek, M. L. Green, et al. Delta-9-THC as an effective antidepressant and appetite-stimulating agent in advanced cancer patients, in The Pharmacology of Marijuana. (Eds. M.C. Braude, S. Szara), Raven Press, New York, 1976, pp. 763-775.
82. K. Nelson, D. Walsh, P. Deeter, F. Sheehan. A phase-II study of delta-9-THC for appetite-stimulation in cancer-associated anorexia. J. Palliat. Care 1994, 10, 14-18.
83. A. Jatoi, H. E. Windschitl, C. L. Loprinzi, J. A. Sloan, S. R. Dakhil, J. A. Mailliard, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia. J. Clin. Oncol. 2002, 29, 567.
84. Cannabis-In-Cachexia-Study-Group, F. Strasser, D. Luftner, K. Possinger, G. Ernst, T. Ruhstaller, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: A multcenter, Phase III, randomized, double-blind, placebo-controlled clinical trial from cannabis-in-cachexia-study-group. J. Clin. Oncol. 2006, 24, 3394.
85. L. Volicer, M. Stelly, J. Morris, J. McLaughlin, B. J. Volicer. Effects of dronabinol on anorexia and disturbed behaviour in patients with Alzheimer's disease. Int. J. Geriatr. Psych. 1997, 12, 913.
86. S. Patel, J. R. Shua-Haim, M. Pass. Safety and efficacy of dronabinol in the treatment of agitation in patients with Alzheimer's disease and anorexia: A retrospective chart review, Eleventh International Congress of the International Psychogeriatric Association, Chicago, August 17-22, 2003.
87. A. W. Zuardi, I. Shirakawa, E. Finkelfarb, I. G. Karniol. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 1982, 76(3), 245.
88. A. W. Zuardi, J. A. Rogdrigues, J. M. Cunha. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl) 1991, 104, 260.
89. D. C. Bosi, J. E. Hallak, S. M. Dursun, J. F. Deakin, A. W. Zuardi. Effects of cannabidiol on (s)-ketamine-induced psychopathology in healthy volunteers. J. Psychopharmacol. 2003, 17, A55.
90. L. E. Long, D. T. Malone, D. A. Taylor. Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 2006, 31, 795.
91. S. Bhattacharyya, J. A. Crippa, P. Allen, R. Martin-Santos, S. Borgwardt, P. Fusar-Poli, et al. Induction of psychosis by delta-9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch. Gen. Psychiat. 2012, 69(1), 27.
92. F. M. Leweke, D. Piomelli, F. Pahlisch, D. Muhl, C. W. Gerth, C. Hoyer, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry 2012, DOI:10.1038/tp.2012.15
93. P. J. Robson, G. W. Guy, V. Di Marzo. Cannabinoids and schizophrenia: Therapeutic prospects. Curr. Pharm. Design 2013, Jun 14. Epub ahead of print http://www.ncbi.nlm.nih.gov/pubmed/23829368
94. M. J. Wallace, B. E. Blair, W. Falenski, B. R. Martin, R. J. DeLorenzo. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J. Pharm. Exp. Ther. 2003, 307, 129.
95. N. A. Jones, A. J. Hill, I. Smith, S. A. Bevan, C.M. Williams, B. J. Whalley, et al. Cannabidiol displays antiepileptoform and antiseizure properties in vitro and in vivo. J. Pharm. Exp. Ther. 2010, 332, 569.
96. A. J. Hill, M. S. Mercier, T. D. Hill, S. E. Glyn, N. A. Jones, Y. Yamasaki, et al. Cannabidivarin is anticonvulsant in mouse and rat. Brit. J. Pharmacol. 2012, 167, 1629.
97. J. M. Cunha, E. A. Carlini, A. E. Pereira, O. L. Ramos, C. Pimentel, R. Gagliardi, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980, 21, 175.
98. F. R. Ames, S. Cridland. Anticonvulsant effect of cannabidiol. S. Afr. Med. J. 1985, 69, 14.
99. B. Trembly, M. Sherman. Double blind clinical study of cannabidiol as a secondary anticonvulsant. Marijuana '90 International Conference on Cannabis and Cannabinoids, 8-11 July, 1990; Kolympari, Crete, International Association for Cannabinoid Medicines, 1990, pp. 5.
100. Mechoulam R., Carlini E.A. Toward drugs derived from cannabis. Naturwissenschaften 1978, 65, 174.
101. F. D. Christopoulou, D. N. Kiortis. An overview of the metabolic effects of rimonabant in randomized controlled trials: Potential for other cannabinoid 1 receptor blockers in obesity. J. Clin. Pharm. Ther. 2011, 36, 10.
102. K. Cahill, M. H. Ussher. Cannabinoid type 1 receptor antagonists for smoking cessation (review). The Cochrane Library 2012. The Cochrane Collaboration, Issue 7. Published by JohnWiley & Sons, Ltd.
103. B. D. Kangas, M. S. Delatte, V. K. Vemuri, G. A. Thakur, S. P. Nikas, K. V. Subramanian, et al. Cannabinoid discrimination and antagonism by CB1 neutral and inverse agonist antagonists. J. Pharm. Exp. Ther. 2013, 344, 561.
104. E. T. Wargent, M. S. Zaibi, C. Silvestri, D. C. Hislop, C. J. Stocker, C. G. Stott, et al. The cannabinoid D9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. Nutr. Diabetes 2013, 3, e68.